Core Viewpoint - The company is actively involved in the development of innovative drugs and has a significant partnership in the DNA immunotherapy field, specifically targeting HPV-related precancerous lesions [1] Group 1: Company Collaboration and Projects - The VGX-3100 project is a key collaboration between the company's subsidiary, Dongfang Lue, and Inovio, focusing on DNA immunotherapy for treating precancerous lesions caused by HPV [1] - Dongfang Lue holds exclusive rights for the development, production, and commercialization of the product in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan [1] Group 2: Company Holdings and Market Position - The company does not hold any shares in Inovio and has no mutual shareholding plans with them [1] - Currently, the company positions itself as a generic drug company but is actively pushing forward with the research and development of innovative drugs such as WYY and ZT [1]